[Form 3] Autolus Therapeutics plc Initial Statement of Beneficial Ownership
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Autolus Therapeutics plc executive Patrick Paul McIlvenny, SVP Finance, reports his initial equity holdings. He holds share options over 150,000 American Depositary Shares with a $1.49 exercise price expiring on October 8, 2035, vesting 25% on October 8, 2026 and monthly thereafter. He also holds options over 148,000 ADS at $1.62 expiring on March 4, 2036, vesting 25% on March 4, 2027 and then in 36 monthly installments. In addition, he has 33,000 restricted share units that vest in four equal annual installments starting on March 4, 2027, each RSU representing one ADS.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
McIlvenny Patrick Paul
Role
SVP Finance
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Restricted Share Units | -- | -- | -- |
Holdings After Transaction:
Share Option (right to buy) — 150,000 shares (Direct);
Restricted Share Units — 33,000 shares (Direct)
Footnotes (1)
- This option vests 25% on October 8, 2026 and the remainder vests in 36 equal monthly installments thereafter. This option vests 25% on March 4, 2027 and the remainder vests in 36 equal monthly installments thereafter. The RSUs vest in four equal annual installments commencing on March 4, 2027. Each RSU represents a contingent right to receive one Issuer American Depositary Share.